1 October 2018 - Rates of Type 1 diabetes among children and youth on the rise globally.
Novo Nordisk Canada announces Tresiba (insulin degludec injection) has received an expanded Health Canada approval for the treatment of paediatric patients (>2 years of age) with Type 1 diabetes mellitus. Tresiba is an ultra-long-acting basal insulin which provides a glucose-lowering effect beyond 42 hours.
The expanded indication of Tresiba follows its first Health Canada approval in August 2017 for the treatment of adults with Type 1 and Type 2 diabetes mellitus. Tresiba has been approved for reimbursement for adults with Type 1 and Type 2 diabetes mellitus in Ontario, effective September 27, 2018, Quebec, effective September 27, 2018, Saskatchewan, effective October 1, 2018, Manitoba, effective October 18, 2018, as well as by the Non-Insured Health Benefits Program, effective September 18, 2018.